Calciphylaxis Cutis Associated With Fibroblast Growth Factor Receptor (FGFR) Inhibitor Therapy: A New Challenge

Specific fibroblast growth factor receptor (FGFR) inhibitors have been developed to treat malignancies harboring fusions or rearrangements in FGFR2 or FGFR3. Here, we report a case of calciphylaxis cutis in association with FGFR inhibitor therapy in a patient with FGFR2 rearranged cholangiocarcinoma...

Descripción completa

Detalles Bibliográficos
Autores principales: Griffith, Paige, Jedrych, Jaroslaw, Sunshine, Joel, Laheru, Daniel A, Yarchoan, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Dermatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860720/
https://www.ncbi.nlm.nih.gov/pubmed/35223258
http://dx.doi.org/10.7759/cureus.21478

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8860720/
https://www.ncbi.nlm.nih.gov/pubmed/35223258
http://dx.doi.org/10.7759/cureus.21478

Ejemplares similares